67 related articles for article (PubMed ID: 483233)
1. Statistical evidence of the German-Austrian secondary prevention trial.
Uberla K
Thromb Haemost; 1979 Feb; 41(1):237-41. PubMed ID: 483233
[No Abstract] [Full Text] [Related]
2. The German-Austrian aspirin trial: a comparison of acetylsalicylic acid, placebo and phenprocoumon in secondary prevention of myocardial infarction. On behalf of the German-Austrian Study Group.
Breddin K; Loew D; Lechner K; Oberla K; Walter E
Circulation; 1980 Dec; 62(6 Pt 2):V63-72. PubMed ID: 6777073
[TBL] [Abstract][Full Text] [Related]
3. Secondary prevention of myocardial infarction. Comparison of acetylsalicylic acid, phenprocoumon and placebo. A multicenter two-year prospective study.
Breddin K; Loew D; Lechner K; Uberla K; Walter E
Thromb Haemost; 1979 Feb; 41(1):225-36. PubMed ID: 483232
[No Abstract] [Full Text] [Related]
4. The role of pharmacotherapy in secondary prevention of myocardial infarction and death.
Gorlin R; Fuster V
Mt Sinai J Med; 1984 Jun; 51(3):229-36. PubMed ID: 6146929
[No Abstract] [Full Text] [Related]
5. [Prevention of sequelae after myocardial infarct. Results, methods and problems of a prospective multi-center study of the effect of acetylsalicylic acid, phenprocoumon and placebo].
Breddin HK; Uberla KK
Verh Dtsch Ges Inn Med; 1980; 86():1338-48. PubMed ID: 7013326
[No Abstract] [Full Text] [Related]
6. Aspirin and secondary mortality after myocardial infarction.
Elwood PC; Sweetnam PM
Circulation; 1980 Dec; 62(6 Pt 2):V53-8. PubMed ID: 7438381
[TBL] [Abstract][Full Text] [Related]
7. [Acetylsalicylic acid in ischemic insult].
Noth J
Dtsch Med Wochenschr; 1998 Feb; 123(9):270. PubMed ID: 9524540
[No Abstract] [Full Text] [Related]
8. Too little aspirin for secondary prevention after acute myocardial infarction in patients at high risk for cardiovascular events: Results from the MITRA study.
Frilling B; Schiele R; Gitt AK; Zahn R; Schneider S; Glunz HG; Gieseler U; Jagodzinski E; Senges J;
Am Heart J; 2004 Aug; 148(2):306-11. PubMed ID: 15309001
[TBL] [Abstract][Full Text] [Related]
9. [Pro and con: Anticoagulation or thrombocyte function inhibitors in the prophylaxis of myocardial infarct? Arguments in favor of thrombocyte function inhibitors].
Breddin K
Internist (Berl); 1980 Jul; 21(7):394-6. PubMed ID: 7007279
[No Abstract] [Full Text] [Related]
10. Reoperation, myocardial infarction and mortality after transurethral and open prostatectomy: a nation-wide, long-term analysis of 23,123 cases.
Madersbacher S; Lackner J; Brössner C; Röhlich M; Stancik I; Willinger M; Schatzl G;
Eur Urol; 2005 Apr; 47(4):499-504. PubMed ID: 15774249
[TBL] [Abstract][Full Text] [Related]
11. The aspirin myocardial infarction study: final results. The Aspirin Myocardial Infarction Study research group.
Circulation; 1980 Dec; 62(6 Pt 2):V79-84. PubMed ID: 7438383
[TBL] [Abstract][Full Text] [Related]
12. Secondary prevention of myocardial infarction.
Davies JA
Int J Clin Pharmacol Res; 1985; 5(5):303-7. PubMed ID: 3905632
[TBL] [Abstract][Full Text] [Related]
13. [Experiences from general practice: use of acetylsalicylic acid and anticoagulants in patients following acute myocardial infarct].
Dahn G; Kothe K
Z Gesamte Inn Med; 1990 Aug; 45(15):439-41. PubMed ID: 2247990
[TBL] [Abstract][Full Text] [Related]
14. A cost-effectiveness analysis of aspirin versus oral anticoagulants after acute myocardial infarction in Italy -- equivalence of costs as a possible case for oral anticoagulants.
Gianetti J; Gensini G; De Caterina R
Thromb Haemost; 1998 Dec; 80(6):887-93. PubMed ID: 9869155
[TBL] [Abstract][Full Text] [Related]
15. Randomized comparative trial of triflusal and aspirin following acute myocardial infarction.
Cruz-Fernández JM; López-Bescós L; García-Dorado D; López García-Aranda V; Cabadés A; Martín-Jadraque L; Velasco JA; Castro-Beiras A; Torres F; Marfil F; Navarro E
Eur Heart J; 2000 Mar; 21(6):457-65. PubMed ID: 10681486
[TBL] [Abstract][Full Text] [Related]
16. Superior prevention of reinfarction by 30 mg/d aspirin compared with 1000 mg/d: results of a two years follow-up study in Cottbus.
Förster W; Hoffmann W
Biomed Biochim Acta; 1988; 47(10-11):S248-51. PubMed ID: 3073765
[TBL] [Abstract][Full Text] [Related]
17. [Secondary prevention of ischemic cardiopathy].
Caruzzo E; Caruzzo C
Cardiologia; 1995 May; 40(5):347-53. PubMed ID: 8529246
[No Abstract] [Full Text] [Related]
18. Drug therapy for prevention of recurrent myocardial infarction.
van der Elst ME; Buurma H; Bouvy ML; de Boer A
Ann Pharmacother; 2003 Oct; 37(10):1465-77. PubMed ID: 14519050
[TBL] [Abstract][Full Text] [Related]
19. [Platelet antiaggregants or anticoagulants in the secondary prevention after myocardial infarct].
Di Pasquale G; Ottani F; Ceré E; Biancoli S; Sassone B; Lombardi A
Recenti Prog Med; 1998 Oct; 89(10):514-9. PubMed ID: 9842255
[TBL] [Abstract][Full Text] [Related]
20. Characterization and clinical course of patients not receiving aspirin for acute myocardial infarction: results from the MITRA and MIR studies.
Frilling B; Schiele R; Gitt AK; Zahn R; Schneider S; Glunz HG; Gieseler U; Baumgärtel B; Asbeck F; Senges J; ;
Am Heart J; 2001 Feb; 141(2):200-5. PubMed ID: 11174332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
